Pivotal registration of Inobrodib
Latest Information Update: 07 Dec 2022
Price :
$35 *
At a glance
- Drugs Inobrodib (Primary)
- Indications Acute myeloid leukaemia; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- 07 Dec 2022 New trial record